NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-19-333 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award.
Notice NOT-DE-19-012 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-040 from the NIH Guide for Grants and Contracts
Notice NOT-DE-19-011 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-131 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-066 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-129 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-327 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.
Notice NOT-ES-19-016 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-029 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-ES-19-011 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.
Funding Opportunity RFA-AG-20-035 from the NIH Guide for Grants and Contracts. This FOA will use the NIH Resource-Related Research Project (R24) mechanism to facilitate the development of research networks to advance research on the basic biology of aging in health disparities. The infrastructure-building aspect of this FOA will be to establish collaborations for subsequent research on the biology of aging underlying health disparities. The intention is to provide a platform for discovery and pilot projects to establish feasibility of novel approaches to be used by these collaborations. For this FOA, the key human population feature of health disparities is accelerated aging.
Funding Opportunity RFA-DK-19-014 from the NIH Guide for Grants and Contracts. The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering andtransformational studies in DEMD topic areas. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere.
Notice NOT-MH-19-041 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-065 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-079 from the NIH Guide for Grants and Contracts
Notice NOT-OH-19-006 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-036 from the NIH Guide for Grants and Contracts
Notice NOT-DK-19-024 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-326 from the NIH Guide for Grants and Contracts. Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (LMICs) seeks to stimulate new and impactful research towards the development of stigma reduction interventions leading to better outcomes for the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH) in LMICs.